Cambium Bio Advances Elate Ocular® Development with Regulatory and Financial Milestones

Regeneus Ltd. ( (AU:CMB) ) has issued an update.

Cambium Bio Limited has made significant progress in the development of its lead product candidate, Elate Ocular®, for dry eye disease. The company has successfully developed a potency bioactivity assay, initiated drug product manufacturing, and advanced negotiations with global CROs for Phase 3 trials. Regulatory milestones include FDA approval of the Phase 3 clinical trial protocol and a successful Type D meeting with the FDA. Financially, Cambium completed a capital raise, securing A$2.0 million, and continued its R&D investments. Looking ahead, the company plans to finalize drug manufacturing, gain regulatory clearance, appoint a CRO partner, and explore strategic partnerships to maximize Elate Ocular®’s commercial potential.

More about Regeneus Ltd.

Cambium Bio Limited is a clinical-stage regenerative medicine company specializing in the development of innovative biologics for ophthalmology and tissue repair applications.

YTD Price Performance: -27.50%

Average Trading Volume: 20,320

Technical Sentiment Signal: Buy

Current Market Cap: A$5.3M

For detailed information about CMB stock, go to TipRanks’ Stock Analysis page.